Abstract：The Vaccine Administration Law of the People’s Republic of China and other relevant laws require that vaccine recipients or their guardians be educated about vaccines and how they work, and described in general the methods and contents of such vaccination education. With the new law and “Standard Operational Procedures for Immunization” as foundation documents, and in consultation with experts at home and abroad, the Chinese Preventive Medicine Association developed a consensus statement about informed consent for vaccination. This consensus statement is written for disease control and prevention health care personnel in vaccination services and describes the educational content of informed consent, a theoretical framework for immunization and immunization knowledge, the informed consent processes, principles of planning for vaccination, and an informed consent form. Part One of the consensus includes the general principles of vaccination and provides specific information on hepatitis B vaccine, Bacillus Calmette-Guérin vaccine, poliomyelitis vaccine, diphtheria, tetanus and pertussis vaccine, measles-containing vaccine, Japanese encephalitis vaccine, meningococcal vaccine, and hepatitis A vaccine.
[1] Doherty M, Buchy P, Standaert B, et al. Vaccine impact: benefits for human health[J]. Vaccine, 2016, 34(52):6707-6714. [2] Matthijsse SM, Hontelez JAC, Naber SK, et al. Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study[J]. J Infect Dis, 2016, 214(6):854-861. [3] Yu W, Lee LA, Liu Y, et al. Vaccine-preventable disease control in the People's Republic of China: 1949-2016[J]. Vaccine, 2018, 36(52):8131-8137. [4] World Health Organization. Considerations regarding consent in vaccinating children and adolescents between 6 and 17 years old[EB/OL].[2020-09-08]. https://www.who.int/immunization/programmes_systems/policies_strategies/consent_note_en.pdf. [5] Centers for Disease Control and Prevention. Vaccine information statement: current VISs[EB/OL].[2020-09-08]. https://www.cdc.gov/vaccines/hcp/vis/current-vis.html. [6] Peggy OM. Vaccines and informed consent[EB/OL].[2020-09-08]. https://www.peggyomara.com/2019/03/11/vaccines-and-informed-consent/. [7] Public Health Branch in Manitoba. Informed consent guidelines for immunization[EB/OL].[2020-09-08]. http://www.manitoba.ca/health/publichealth/cdc/protocol/consentguidelines.pdf. [8] British Columbia Centers for Disease Control and Prevention. Communicable disease control manual. Chapter 2 Immunization. Appendix A-Informed consent for immunization[EB/OL].[2020-09-08]. http://www.bccdc.ca/health-professionals/clinical-resources/informed-consent-for-immunization. [9] 王军芬. 医疗知情同意效果层次初探[J].中国医学伦理学, 2016, 29(1):148-150. [10] Cocanour CS. Informed consent-it’s more than a signature on a piece of paper[J]. Am J Surg, 2017, 214(6):993-997. [11] 朱伟. 知情同意:定义、模式和挑战[J].生命科学, 2012, 24(11):1243-1249. [12] 钱晓华, 杨平, 伍平, 等. 实施接种疫苗告知制前后免疫接种率和不良反应发生率分析[J].中国计划免疫, 2005, 11(4):306-308. [13] 占小春, 黄新坤, 热娜·买买提. 签订疫苗接种知情同意书提高接种儿童家长健康教育效果[J].护理学杂志, 2011, 26(13):13-13. [14] 陈胜利, 杨建伟, 任宏伟. 预防接种门诊的告知义务与受种对象的知情同意权[J].职业与健康, 2008, 24(24):2724-2726. [15] 舒国滢. 法理学导论[M]. 2版. 北京:北京大学出版社, 2012:147-148. [16] 翟笑枫, 董惠娟, 陈喆. 沟通漏斗效应与中医师承制教育[J].中国中医药现代远程教育, 2013, 11(11):61-62. [17] MacDonald NE, Sage Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants[J]. Vaccine, 2015, 33(34):4161-4164. [18] Yu W, Cao L, Liu Y, et al. Two media-reported vaccine events in China from 2013 to 2016: impact on confidence and vaccine utilization[J]. Vaccine, 2020, 38(34):5541-5547. [19] Zhou M, Qu S, Zhao L, et al. Trust collapse caused by the Changsheng vaccine crisis in China[J]. Vaccine, 2019, 37(26):3419-3425. [20] Yu W, Liu D, Zheng J, et al. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China[J]. Int J Epidemiol, 2016, 45(2):441-449. [21] MacDonald NE, Butler R, Dubé È. Addressing barriers to vaccine acceptance: an overview[J]. Hum Vaccin Immunother, 2018, 14(1):218-224. [22] Dudley MZ, Privor-Dumm L, Dubé È, et al. Words matter: vaccine hesitancy, vaccine demand, vaccine confidence, herd immunity and mandatory vaccination[J]. Vaccine, 2020, 38(4):709-711. [23] 史金晶, 唐智敏, 余文周. 疫苗犹豫现状及其应对措施[J].中国疫苗和免疫, 2019, 25(4):481-486. [24] 宋洁玉, 汪萱怡. 疫苗犹豫及其引发的后果[J].国际流行病学传染病学杂志, 2019, 46(3):173-174. [25] 于伟, 周波青, 胡瑜超, 等. 预防接种家长学校集中告知的效果评价[J].预防医学, 2017, 29(2):212-213. [26] 余文周, 李放军, 张振国, 等. 2013年媒体报道乙型肝炎疫苗事件后部分省儿童家长对预防接种信任度的调查分析[J].中国疫苗和免疫, 2014, 20(3):233-236. [27] 姜仁杰, 沈进进, 管书慧, 等. 盐城市开展免疫规划家长课堂的实践与思考[J].中国健康教育, 2014, 30(12):1151-1153. [28] 周勇, 倪倩钰, 吴江南, 等. 微信公众号上实现全省疫苗接种知情告知的实践[J].海峡预防医学杂志, 2016, 22(1):80-81. [29] World Health Organization. Global manual on surveillance of adverse events following immunization[EB/OL].[2020-12-14]. https://www.who.int/vaccine_safety/publications/aefi_surveillance/en/. [30] 迮文远. 预防接种手册[M]. 上海:上海科学技术文献出版社, 1997:1-35. [31] 谢广中, 刁连东, 王树巧. 免疫接种的反应和处理[M]. 2版. 上海:上海科学技术出版社, 2004. [32] Iannelli V. How do you provide informed consent to vaccination[EB/OL].[2020-09-08]. https://vaxopedia.org/2018/12/05/how-do-you-provide-informed-consent-to-vaccination/. [33] 袁杰, 王振江, 赵宁, 等. 中华人民共和国疫苗管理法释义[M]. 北京:中国民主法制出版社, 2019:125. [34] Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences[J]. N Engl J Med, 2004, 350(11):1118-1129. [35] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J].实用肝脏病杂志, 2020, 23(1):32. [36] World Health Organization. Hepatitis B[EB/OL].[2020-12-07]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. [37] 崔富强, 龚晓红, 陈园生, 等. 中国不同省份1992—2006年乙型肝炎疫苗预防接种进展及乙型肝炎病毒表面抗原携带率变化分析[J].中国疫苗和免疫, 2012, 18(1):6-13. [38] van Den Ende C, Marano C, van Ahee A, et al. The immunogenicity of GSK's recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience[J]. Expert Rev Vaccines, 2017, 16(8):789-809. [39] Leroux-Roels G, Abraham B, Fourneau M, et al. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents[J]. Vaccine, 2000, 19(7-8):937-942. [40] Clemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of low-and non-responders after a standard three dose hepatitis B vaccine schedule-results of a post-marketing surveillance[J]. Vaccine, 1997, 15(4):349-352. [41] 梁争论, 李艳萍, 荆庆, 等. 一种新型重组(汉逊酵母)乙型肝炎疫苗人体安全性和免疫效果考核[J].中国计划免疫, 2004, 10(4):193-197. [42] 梁争论, 李河民, 荆庆, 等. 乙型肝炎基因工程疫苗免疫原性和免疫效果研究[J].医学研究通讯, 2001, (8):8-10. [43] 颜丙玉, 张丽, 吕静静, 等. 成人重组酿酒酵母和汉逊酵母乙型肝炎疫苗免疫应答及相关因素研究[J].中华流行病学杂志, 2012, 33(9):988-989. [44] Jack AD,Hall AJ,Maine N,et al. What level of hepatitis B antibody is protective?[J]. J Infect Dis, 1999, 179(2):489-492. [45] Resti M, Azzari C, Mannelli F, et al. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?[J]. Vaccine, 1997, 15(12-13):1338-1340. [46] Viviani S, Jack A, Hall AJ, et al. Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age[J]. Vaccine, 1999, 17(23-24):2946-2950. [47] Huang LM, Chiang BL, Lee CY, et al. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen[J]. Hepatology, 1999, 29(3):954-959. [48] Mintai Z, Kezhou L, Lieming D, et al. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents[J]. Clin Infect Dis, 1993, 16(1):165-167. [49] Banatvala JE, Van Damme P. Hepatitis B vaccine-do we need boosters?[J]. J Viral Hepat, 2003, 10(1):1-6. [50] Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose[J]. J Infect Dis, 2016, 214(1):16-22. [51] Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial[J]. PLoS Med, 2014, 11(12):e1001774. [52] Lin AW, Wong KH. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong[J]. J Hepatol, 2013, 59(6):1363-1364. [53] 叶家楷, 李克莉, 许涤沙, 等. 中国2013年疑似预防接种异常反应信息管理系统数据分析[J]. 中国疫苗和免疫, 2015, 21(2):121-131,200. [54] 李兰娟, 任红. 传染病学[M]. 第9版. 北京:人民卫生出版社, 2018:55. [55] 高静韬, 刘宇红. 2019年世界卫生组织全球结核病报告要点解读[J].国际呼吸杂志, 2020, 40(3):161-166. [56] 刘剑君, 幺鸿雁. 我国结核病的流行现状和防治对策[J].预防医学论坛, 2006, 12(5):3. [57] 王黎霞, 成诗明, 陈明亭, 等. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志, 2012, 34(8):485-508. [58] 赵大海, 徐飚. 结核病与贫穷[J].中国防痨杂志, 2004, 26(3):177-179. [59] 周平, 张敏, 周北燕, 等. 卡介苗接种后婴儿细胞免疫状态研究[J].中国儿童保健杂志, 2012, 20(1):73-75. [60] Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis[J]. BMJ, 2014, 349:g4643. [61] Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials[J]. Clin Infect Dis, 2014, 58(4):470-480. [62] 陈才, 高艳霞, 韩凤. 310例早产儿卡介苗接种后免疫效果回顾性分析[J].医学食疗与健康, 2020, 18(7):190-191. [63] 李克莉, 刘大卫, 武文娣, 等. 2009—2010年全国卡介苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫, 2012, 18(3):252-260, 281. [64] 胡冉, 刘元宝, 康国栋, 等. 2015—2017年江苏省卡介苗不良反应监测分析[J].江苏预防医学, 2019, 30(2):193-194. [65] 彭晓雯. 中国9省卡介苗预防接种安全性监测分析评价[D]. 北京:中国疾病预防控制中心, 2011. [66] 彭晓雯. 卡介苗预防接种安全性综述[J].中国疫苗和免疫, 2010, 16(6):558-563. [67] Rani SH, Vijayalakshmi V, Sunil K, et al. Cell mediated immunity in children with scar-failure following BCG vaccination[J]. Indian Pediatr, 1998, 35(2):123-127. [68] Jenkins HE, Yuen CM, Rodriguez CA, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2017, 17(3):285-295. [69] 应文静. 卡介苗感染的遗传免疫缺陷研究[D]. 上海:复旦大学, 2012. [70] 曾雪霞, 陈碧玉, 潘婷婷, 等. 海南省2008—2018年常见卡介苗预防接种不良反应处置[J].中国疫苗和免疫, 2019, 25(4):459-463. [71] 陈凤, 蒋利萍, 朱朝敏. 小儿卡介苗接种不良反应73例临床分析[J].中华传染病杂志, 2012, 30(12):747-749. [72] Carniel EF, Morcillo AM, Blotta MH, et al. Immunogenicity and safety of combined intradermal recombinant hepatitis B with BCG vaccines at birth[J]. Vaccine, 2008, 26(5):647-652. [73] Ehrenfeld E, Diminggo E, Ross RP, et al. The picornaviruses[M]. Washington DC: ASM Press, 2010:155. [74] Committee on Typing of the National Foundation for Infantile Paralysis. Immunologic classification of poliomyelitis viruses. I. A cooperative program for the typing of one hundred strains[J]. Am J Hyg, 1951, 54(2):191-204. [75] Sabin AB. Epidemiologic patterns of poliomyelitis in different parts of the world[C]. The First International Poliomyelitis Conference, 1992. [76] World Health Organization. Polio vaccines: WHO position paper, January 2014--recommendations[J]. Vaccine, 2014, 32(33):4117-4118. [77] World Health Organization. Report of the interim meeting of the Technical Consultative Group (TCG) on the global eradication of poliomyelitis[C]. Geneva, 2003. [78] Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria[J]. N Engl J Med, 2010, 362(25):2360-2369. [79] Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)[J]. Risk Anal, 2013, 33(4):680-702. [80] Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs[J]. BMC Infect Dis, 2015, 15(1):379. [81] World Health Organization. Grading of scientific evidence-table III: antibody persistence[EB/OL].[2020-09-08]. http://www.who.int/entity/immunization/polio_grad_duration_protection.pdf. [82] Centers for Disease Control and Prevention. Certification of poliomyelitis eradication--the Americas, 1994[J]. MMWR Morb Mortal Wkly Rep, 1994, 43(39):720-722. [83] Centers for Disease Control and Prevention. Certification of poliomyelitis eradication--Western Pacific Region, October 2000[J]. MMWR Morb Mortal Wkly Rep, 2001, 50(1):1-3. [84] Centers for Disease Control and Prevention. Certification of poliomyelitis eradication--European Region, June 2002[J]. MMWR Morb Mortal Wkly Rep, 2002, 51(26):572-574. [85] World Health Organization. Polio-free certification of the WHO South-East Asia Region, March 2014[J]. Wkly Epidemiol Rec, 2014, 89(44):500-504. [86] Faden H, Modlin JF, Thoms ML, et al. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses[J]. J Infect Dis, 1990, 162(6):1291-1297. [87] Plotkin SA, Orenstein WA, Paul A, et al. Vaccines[M]. 6th ed. Philadelphia: ELSEVIER, 2011. [88] 李克莉, 张丽娜, 叶家楷, 等. 中国2017年疑似预防接种异常反应监测[J].中国疫苗和免疫, 2020, 26(1):9-18. [89] 迮文远, 刁连东, 徐爱强. 计划免疫学[M]. 第2版. 上海:上海科学技术文献出版社, 2001:15-33. [90] 宁桂军, 高源, 吴丹, 等. 中国2011—2017年百日咳流行病学特征分析[J].中国疫苗和免疫, 2018, 24(3):264-267, 273. [91] 中国慢性病预防与控制. 卫生部公布我国伤害预防报告[J]. 中国慢性病预防与控制, 2007, 15(5):409. [92] 陈秀丽, 徐岷田. 无细胞百白破联合疫苗安全性和免疫原性研究[J].医学研究杂志, 2008, 37(10):115-116. [93] 胡家垒, 李贵凡, 胡月梅, 等. 吸附无细胞百白破联合疫苗的安全性和免疫原性研究[J].江苏预防医学, 2017, 28(1):9-11, 14. [94] 来亦超, 马福宝, 张晋琳, 等. 无细胞百白破联合疫苗安全性和免疫原性研究[J].现代预防医学, 2007, 34(22):4250-4252,4255. [95] 黄莉荣, 李艳萍, 张庶民, 等. 无细胞百白破联合疫苗的安全性及免疫原性研究[J].应用预防医学, 2009, 15(2):111-114. [96] 田秀梅, 潘红星, 张艺飓, 等. 吸附无细胞百白破联合疫苗的安全性及免疫原性研究[C]. 第三次全国免疫诊断暨疫苗学术研讨会论文集, 南京, 2007:183-188. [97] 李艳萍, 李凤祥, 侯启明, 等. 中国婴幼儿接种吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌(结合)联合疫苗的安全性和免疫原性研究[J].中华流行病学杂志, 2011, 32(8):808-815. [98] 邹光荣, 兰红, 李恒星, 等. 吸附无细胞百白破联合疫苗的安全性[J]. 中国生物制品学杂志, 2013, 26(11):1637-1640. [99] 刘大卫, 郭飚, 曹玲生, 等. 吸附无细胞和全细胞百白破联合疫苗上市后预防接种安全性的比较分析[J].中国疫苗和免疫, 2008, 14(2):97-102. [100] 邓新娅, 李秀岭, 魏章华, 等. 无细胞百白破b型流感嗜血杆菌联合疫苗大规模上市后安全性观察[J].中国疫苗和免疫, 2018, 24(2):182-185. [101] 白云骅, 李淑萍, 丁舒, 等. 北京市朝阳区12 241名婴幼儿三个部位接种无细胞百白破b型流感嗜血杆菌联合疫苗安全性分析[J].中华预防医学杂志, 2020, 54(9):953-957. [102] 胡云峰. 接种白破疫苗致过敏性紫癜合并紫癜性肾炎1例分析[J].海峡预防医学杂志, 2016, 22(1):78-79. [103] Rota PA, Brown K, Mankertz A, et al. Global distribution of measles genotypes and measles molecular epidemiology[J]. J Infect Dis, 2011, 204 (Suppl 1):S514-523. [104] Rota PA, Featherstone DA, Bellini WJ. Molecular epidemiology of measles virus[J]. Curr Top Microbiol Immunol, 2009, 330(6):129-150. [105] Wu L, Bai Z, Li Y, et al. Wild type mumps viruses circulating in China establish a new genotype[J]. Vaccine, 1998, 16(2-3):281-285. [106] 肖芳, 施勇, 龚甜, 等. 2014年江西省流行性腮腺炎感染状况及部分地区健康人群流行性腮腺炎抗体水平调查[J].实验与检验医学, 2017, 35(2):156-159. [107] 司源, 马钰, 李平, 等. 2011年陕西省流行性腮腺炎病毒株基因型别分析[J].中华疾病控制杂志, 2014, 18(2):176-177. [108] 陈萌, 崔爱利, 王斌, 等. 北京市2016年发现流行性腮腺炎G基因型病毒[J].病毒学报, 2017, 33(5):706-711. [109] 李东, 陈致飞, 杨秀惠, 等. 福建省2005—2017年流行性腮腺炎疫情及病原学监测分析[J].中华流行病学杂志, 2018, 39(10):1356-1361. [110] World Health Organization. Rubella virus nomenclature update: 2013[J]. Wkly Epidemiol Rec, 2013, 88(32):337-343. [111] 王常银, 朱贞, 徐爱强, 等. 2000—2007年山东省风疹病毒分子流行病学研究[J].病毒学报, 2010, 26(6):471-476. [112] 周淑洁, 朱贞, 陈霞, 等. 安徽省1999—2011年风疹病毒分子流行病学研究[J].中国疫苗和免疫, 2013, 19(2):136-141. [113] 朱贞, 许文波, 毛乃颖, 等. 2003—2007年中国风疹病毒基因特征分析[J]. 病毒学报, 2008, 24(1):7-16. [114] Stadlmann S, Lenggenhager DM, Alves VA, et al. Histopathologic characteristics of the transitional stage of measles-associated appendicitis: case report and review of the literature[J]. Hum Pathol, 2011, 42(2):285-290. [115] Ivancic-Jelecki J, Baricevic M, Santak M, et al. The first genetic characterization of a D4 measles virus strain derived from a patient with subacute sclerosing panencephalitis[J]. Infect Genet Evol, 2013, 17(3):71-78. [116] 朱军礼, 王凤英, 金祝平, 等. 疫苗时代麻疹临床症状特征分析及监测病例定义评价[J].中国疫苗和免疫, 2010, 16(5):430-434. [117] 田军, 田维. 流行性腮腺炎患者80例的临床特点[J].中国社区医师, 2018, 34(22):50, 52. [118] 李思阳, 李德春, 田英俊. 6 956例流行性腮腺炎流行病学及临床特点调查分析[J].中国现代医生, 2016, 54(28):128-130, 169. [119] 李燕, 马静, 殷大鹏. 风疹疫苗:世界卫生组织立场文件[J].中国疫苗和免疫, 2011, 17(6):565-568. [120] Frey TK. Molecular biology of rubella virus[J]. Adv Virus Res, 1994, 44(44):69-160. [121] Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity[J]. Clin Microbiol Rev, 2000, 13(4):571-587. [122] 蓝荣伟. 全球麻疹流行病学研究进展[J].热带医学杂志, 2013, 13(12):1557-1560. [123] 张未, 许红梅. 全球麻疹的流行病学研究进展[J].国际检验医学杂志, 2011, 32(1):73-75. [124] 赵苗苗, 苏琪茹, 马超, 等. 中国2005—2016年风疹突发公共卫生事件流行病学特征[J].中国疫苗和免疫, 2019, 25(3):243-247. [125] He H, Chen E, Chen H, et al. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children[J]. Vaccine, 2014, 32(31):4001-4005. [126] 陈洁, 陈深侠, 凌罗亚, 等. 国产麻疹流行性腮腺炎风疹联合疫苗初免效果及免疫程序探讨[J].中国计划免疫, 2006, 12(3):215-217. [127] 刘国华, 方悍华, 冯子健, 等. 冻干麻疹-腮腺炎-风疹三联活疫苗免疫安全性及免疫学效果观察[J].中华流行病学杂志, 2002, 23(6):435-437. [128] 刘卫民, 何梅英, 卓菲. 国产麻疹-腮腺炎-风疹联合疫苗与麻疹疫苗的免疫效果评价[J].实用预防医学, 2010, 17(9):1754-1755. [129] 陶育晖, 杨晓智, 李刚, 等. 长春市2006年健康人群麻疹、风疹、腮腺炎抗体水平分析[J].中国卫生工程学, 2007, 6(6):372-374. [130] 武滨, 俞爱琴, 李晋玲, 等. 麻疹-腮腺炎-风疹三联疫苗扩大免疫安全性及免疫效果研究[J]. 山西医药杂志, 2009, 38(3):250-251. [131] 何寒青, 严睿, 马燕丽, 等. 4岁儿童麻疹-流行性腮腺炎-风疹联合减毒活疫苗加强免疫的安全性和免疫原性观察[J].中华微生物学和免疫学杂志, 2018, 38(1):62-66. [132] 胡家瑜, 施燕, 倪莹箐, 等. 麻疹 流行性腮腺炎 风疹联合疫苗2剂免疫的效果观察[J].中国计划免疫, 2004, 10(4):221-224. [133] 符剑, 何寒青, 陈恩富, 等. 国产与进口麻疹-流行性腮腺炎-风疹联合减毒活疫苗的免疫原性和安全性观察[J].中国疫苗和免疫, 2013, 19(3):222-226, 249. [134] 储艳, 陆玉忠, 陶红, 等. 国产麻腮风联合减毒活疫苗的安全性及免疫原性[J].中国生物制品学杂志, 2011, 24(6):707-710. [135] 吴艳梅. 国产与进口麻疹-腮腺炎-风疹三联疫苗免疫原性与安全性的系统评价[J].中国初级卫生保健, 2015, 29(12):61-64. [136] Levin A, Burgess C, Garrison LP, et al. Global eradication of measles: an epidemiologic and economic evaluation[J]. J Infect Dis, 2011, 204 (Suppl 1):98-106. [137] 梁祁, 周伟忠, 李靖欣, 等. 麻疹风疹联合减毒活疫苗的安全性及免疫原性观察[J]. 中国生物制品学杂志, 2011, 24(12):1490-1493. [138] 刁琳琪, 张延炀, 康锴, 等. 麻疹-风疹联合疫苗的安全性和免疫原性观察[J].中国计划免疫, 2006, 126:495-496. [139] Hviid A, Rubin S, Mühlemann K. Mumps[J]. Lancet, 2008, 371(9616):932-944. [140] World Health Organization. Measles vaccines: WHO position paper, April 2017-Recommendations[J]. Vaccine, 2019, 37(2):219-222. [141] 王玲, 吕宏亮, 王世文, 等. 儿童流行性腮腺炎血清流行病学及疫苗免疫效果研究[J].中国计划免疫, 2002, 8(1):36-38. [142] 傅传喜, 梁建华, 王大虎, 等. 疫苗对流行性腮腺炎保护效果的配对病例对照研究[J].中国疫苗和免疫, 2008, 14(5):448-451. [143] 徐维祯, 张国民, 梁爽, 等. 流行性腮腺炎减毒活疫苗免疫学效果和保护效果的系统评价[J].中国疫苗和免疫, 2011, 17(5):426-430, 450. [144] 张晓曙, 李红, 唐宇, 等. 国产单价腮腺炎减毒活疫苗加强免疫的免疫原性和安全性观察[J].中国疫苗和免疫, 2018, 24(5):535-538. [145] World Health Organization. Mumps virus vaccines[J]. Wkly Epidemiol Rec, 2007, 82(7):51-60. [146] Peltola H, Jokinen S, Paunio M, et al. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme[J]. Lancet Infect Dis, 2008, 12(8):796-803. [147] 马超, 郝利新, 苏琪茹, 等. 世界卫生组织194个成员国麻疹、流行性腮腺炎、风疹减毒活疫苗常规免疫程序、报告接种率与发病水平现状分析[J].中国疫苗和免疫, 2015, 21(3):241-247, 254. [148] 周春碚, 肖达勇, 夏宇, 等. 重庆市武隆县某小学流行性腮腺炎暴发疫情调查[J].实用预防医学, 2017, 24(7):844-848. [149] 吕海英, 王翠玲. 流行性腮腺炎疫苗在学校暴发疫情中的保护效果[J]. 中国学校卫生, 2015, 36(12):1845-1847. [150] 宋会荣, 贾娜. 不同流行性腮腺炎疫苗接种率及剂次保护效果比较评价[J].世界最新医学信息文摘, 2018, 18(48):296. [151] 李海军. 麻疹—风疹联合疫苗、麻疹—腮腺炎—风疹联合疫苗儿童初免安全性及免疫学效果观察[D]. 中国疾病预防控制中心, 2010. [152] 梁燕, 张颖丽, 廖芸, 等. F基因型腮腺炎减毒活疫苗的临床前安全性评价[J].医学研究杂志, 2013, 42(5):30-34. [153] World Health Organization, 刘文婷, 李艺星. 世界卫生组织关于流行性乙型脑炎的立场文件(2015年2月)[J].中国疫苗和免疫, 2015, 21(6):716-720. [154] 吴丹, 尹遵栋, 李军宏, 等. 中国2014—2018年流行性乙型脑炎流行病学特征[J].中国疫苗和免疫, 2020, 26(1):1-4. [155] 敖坚, 俞永新, 吴惠英. SA14-14-2减毒活疫苗对人体的安全性和免疫性[J]. 中华微生物学和学杂志, 1983, 3(4):245-248. [156] 贾丽丽, 郑铮, 俞永新. 流行性乙型脑炎流行区内儿童接种乙脑减毒活疫苗后的免疫应答[J]. 中国人兽共患病杂志, 1995, 11(6):343-344. [157] 刘欣玉, 鲁旭, 赵丹华, 等. 乙型脑炎减毒活疫苗对中国主要流行基因型毒株的免疫效果[J].中国生物制品学杂志, 2019, 32(9):1006-1009. [158] Gatchalian S, Yao Y, Zhou B, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants[J]. Vaccine, 2008, 26(18):2234-2241. [159] 周荔葆, 赵新, 吴栩涛, 等. Vero细胞乙型脑炎灭活疫苗的接种反应及免疫效果观察[J].中国生物制品学杂志, 2009, 22(8):809-811. [160] 陈品全, 周本立, 马文信, 等. SA14-14-2株乙型脑炎活疫苗流行病学效果观察[J]. 中国生物制品学杂志, 1992, 5(3):135-137. [161] 周本立, 贾丽丽, 许先兰, 等. 流行性乙型脑炎减毒活疫苗大面积接种后安全性和流行病学效果的5年观察[J].中华流行病学杂志, 1999, 20(1):38-41. [162] 周本立, 张岷, 陈品全, 等. 流行性乙型脑炎活疫苗11年的流行病学效果[J].中国生物制品学杂志, 2001, 14(3):183-185. [163] Bista MB, Banerjee MK, Shin SH, et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study[J]. Lancet, 2001, 358(9284):791-795. [164] Ohrr H, Tandan JB, Sohn YM, et al. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study[J]. Lancet, 2005, 366(9494):1375-1378. [165] Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization[J]. Vaccine, 2007, 25(27):5041-5045. [166] Kaltenbock A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age[J]. Vaccine, 2010, 28(3):834-839. [167] Dubischar-Kastner K. Safety and immunogenicity of the inactivated Japanese encephalitis vaccine IXIARO ®, IC51, in Filipino children aged 2 months to<18 years[C]. The Asia Pacific Travel Health Conference, 2012. [168] Takeshita N, Lim CK, Mizuno Y, et al. Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults[J]. J Infect Chemother, 2014, 20(4):238-242. [169] 马文信, 俞永新, 王寿贵, 等. 流行性乙型脑炎活疫苗大面积人体接种的安全性和血清学效果观察[J].中国生物制品学杂志, 1993, 6(4):188-191. [170] Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26, 239 subjects[J]. J Infect Dis, 1997, 176(5):1366-1369. [171] Liu Y, Lin H, Zhu Q, et al. Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012[J]. Vaccine, 2014, 32(15):1768-1773. [172] 尹遵栋, 罗会明, 高君, 等. 流行性乙型脑炎灭活疫苗(非洲绿猴肾细胞)和减毒活疫苗不同接种方案的安全性观察分析[J].中国疫苗和免疫, 2011, 17(3):195-200. [173] 李永成, 张之伦, 张颖, 等. 冻干流行性乙型脑炎灭活疫苗(非洲绿猴肾细胞)和减毒活疫苗序贯免疫的安全性评价[J].中国疫苗和免疫, 2011, 17(2):155-157. [174] 中华人民共和国国家卫生和计划生育委员会. 国家免疫规划疫苗儿童免疫程序及说明(2016年版)[J].中国病毒病杂志, 2017, 7(2):81-86. [175] 中华人民共和国国家药典委员会. 中华人民共和国药典(第三部)[M]. 北京:中国医药科技出版社, 2015:333. [176] World Health Organization. Meningococcal vaccines: WHO position paper, November 2011[J]. Wkly Epidemiol Rec, 2011, 86(47):521-539. [177] 国家卫生健康委员会. 流行性脑脊髓膜炎诊断:WS 295-2019[S]. 北京:中国标准出版社,2019:1-15. [178] 中华预防医学会, 姚开虎, 刘钢. 脑膜炎奈瑟菌感染的临床学进展[J].中国疫苗和免疫, 2019, 25(2):238-242. [179] 中华预防医学会, 吴疆.中国脑膜炎球菌疫苗预防接种专家共识[J].中国疫苗和免疫, 2019, 25(1):96-101. [180] Granoff DM,Gupta RK,Belshe RB,et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination[J]. J Infect Dis, 1998, 178(3):870-874. [181] Vodopija I,Baklaic Z,Hauser P,et al. Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide[J]. Infect Immun, 1983, 42(2):599-604. [182] 张延龄, 张晖. 疫苗学[M]. 北京:科学出版社, 2004:156. [183] Baxendale HE, Davis Z, White HN, et al. Immunogenetic analysis of the immune response to pneumococcal polysaccharide[J]. Eur J Immunol, 2000, 30(4):1214-1223. [184] Ambrosch F Fau-Wiedermann G, Wiedermann G Fau-Crooy P, Fau-George AM, et al. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine[J]. Bull World Health Organ, 1983, 61(2):317-323. [185] Gardner P. Clinical practice. Prevention of meningococcal disease[J]. N Engl J Med, 2006, 355(14):1466-1473. [186] 潘金仁, 陈会红, 李寿俊, 等. A群C群脑膜炎球菌多糖结合疫苗6月龄儿童初次免疫效果[J].中国疫苗和免疫, 2015, 21(5):511-514. [187] 秦才珍, 王宏军, 陶红, 等. 不同剂量A/C群脑膜炎球菌多糖结合疫苗免疫学效果评价[J].中国疫苗和免疫, 2010, 16(5):462-465. [188] 周海, 李亚南, 谈晔, 等. A、C群脑膜炎球菌多糖结合疫苗免疫效果观察[J].中华预防医学杂志, 2014, 48(8):737-738. [189] Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US air force personnel[J]. J Infect Dis, 1994, 169(4):847-852. [190] 徐鹭, 路坚, 丁筱竹. 南京市健康儿童流脑A群和C群抗体水平监测及A+C群流脑疫苗免疫效果分析[J].现代预防医学, 2009, 36(11):2048-2049,2051. [191] 郑佳, 朱向国, 刘刚, 等. A群C群脑膜炎球菌多糖结合疫苗的免疫原性及免疫持久性观察[J].中国生物制品学杂志, 2015, 28(7):707-710. [192] 董柏青, 叶强, 崔萱林, 等. A+C群脑膜炎球菌多糖疫苗安全性评估[J].中华流行病学杂志, 2007, 28(5):417-421. [193] 何莉, 李荣成, 李亚南, 等. A+C群脑膜炎球菌多糖疫苗安全性和免疫原性的研究[J].中华流行病学杂志, 2007, 28(5):422-425. [194] 武文娣, 刘大卫, 李克莉, 等. 2010—2012年中国脑膜炎球菌疫苗预防接种不良反应监测分析[J].中国药物评价, 2014, (2):117-121, 128. [195] World Health Organization. WHO position paper on hepatitis A vaccines: June 2012-recommendations[J]. Vaccine, 2013, 31(2):285-286. [196] Sun XJ, Zhang GM, Zhou RJ, et al. Changes in the epidemiology of hepatitis A in three socio-economic regions of China, 1990-2017[J]. Infect Dis Poverty, 2019, 8(1):80. [197] Ma F,Yang J,Kang G,et al. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study[J]. Clin Microbiol Infect, 2016, 22(9):811.e9-811.e15. [198] Liu XE, Wushouer F, Gou A, et al. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China[J]. Hum Vaccin Immunother, 2013, 9(7):1460-1465. [199] Zheng H, Chen Y, Wang F, et al. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose[J]. Vaccine, 2011, 29(48):9098-9103. [200] 王华庆, 随海田. 甲型肝炎减毒活疫苗保护效果的meta分析[J].中国疫苗和免疫, 2008, 14(1):1-6. [201] Sun X, Wang F, Zheng H, et al. The impact of expanded program on immunization with live attenuated and inactivated hepatitis A vaccines in China, 2004-2016[J]. Vaccine, 2018, 36(10):1279-1284. [202] Wang Z,Chen Y,Xie S,et al. Changing epidemiological characteristics of hepatitis A in Zhejiang Province, China: increased susceptibility in adults[J]. PLoS One, 2016, 11(4):e0153804. [203] Cui F, Liang X, Wang F, et al. Development, production, and postmarketing surveillance of hepatitis A vaccines in China[J]. J Epidemiol, 2014, 24(3):169-177. [204] Levine H, Kopel E, Anis E, et al. The impact of a national routine immunisation programme initiated in 1999 on hepatitis A incidence in Israel, 1993 to 2012[J]. Euro Surveill, 2015, 20(7):3-10. [205] Souto F,de Brito WI,Fontes C. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil[J]. Vaccine, 2019, 37(6):771-775. [206] Im JH,Woo HT,Ha B,et al. Effectiveness of single-dose administration of inactivated hepatitis A virus vaccination in the Republic of Korea armed forces, 2013-2016[J]. J Viral Hepat, 2020, 27(5):537-539. [207] Rao S, Mao JS, Motlekar S, et al. A review of immunogenicity and tolerability of live attenuated hepatitis A vaccine in children[J]. Hum Vaccin Immunother, 2016, 12(12):3160-3165. [208] 梁辉, 潘雪娇, 郭静, 等. 浙江省2010—2014年甲型肝炎疫苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫, 2015, 21(6):647-651, 635. [209] Shi N, Rasuli A, Thollot Y. Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study[J]. Hum Vaccin Immunother, 2019, 15(3):748-754. [210] 许涤沙, 李克莉, 武文娣, 等. 中国2016年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫, 2018, 24(3):299-309, 322.
2021, Vol. 28 
